X4 Pharmaceuticals stockholders at the Annual Meeting elected three directors, ratified PwC as auditors, approved the Second Amended and Restated 2017 Equity Incentive Plan increasing shares by 1,500,000, and supported executive compensation.
Key takeaways
Stockholders approved Second Amended and Restated 2017 Equity Incentive Plan, adding 1,500,000 shares for issuance.
Gary J. Bridger, Ph.D., Françoise De Craecker, and Murray W. Stewart, M.D. elected as directors until 2029 Annual Meeting.
Proposal 3 passed with 58,679,552 FOR vs. 17,684,140 AGAINST, despite broker non-votes of 6,474,104.
Ratified PricewaterhouseCoopers LLP as independent auditors for fiscal year ending December 31, 2026.
Non-binding say-on-pay for named executive officers approved with 70,932,142 FOR votes.